Part of the weekly research here at The Acquirer’s Multiple features some of the top picks from our Stock Screeners and some top investors who are holding these same picks in their portfolios. Investors such as Warren Buffett, Joel Greenblatt, Carl Icahn, Jim Simons, Prem Watsa, Jeremy Grantham, Seth Klarman, Ray Dalio, and Howard Marks. The top investor data is provided from their latest 13F’s. This week we’ll take a look at:
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)
Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon focused efforts on two drugs: sotagliflozin in diabetes, which is partnered with Sanofi, and Xermelo (telotristat etiprate) in carcinoid syndrome, which is partnered with Ipsen outside the U.S. Early-stage programs include SGLT1 inhibitor LX2761 and neuropathic pain drug LX9211.
A quick look at the price chart below for Lexicon Pharmaceuticals shows us that the stock is down 40% in the past twelve months. We currently have the stock trading on an Acquirer’s Multiple of 1.80 which means that it remains undervalued.
Superinvestors who currently hold positions in Lexicon Pharmaceuticals include:
Israel Englander – 1,220,629 total shares
Jim Simons – 665,379 total shares
Steve Cohen – 528,100 total shares
Ken Griffin – 204,968 total shares
Michael Gelband – 136,840 total shares
Cliff Asness – 43,810 total shares
For all the latest news and podcasts, join our free newsletter here.
Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple: